Literature DB >> 2877084

Alpha-1 adrenoceptor antagonist effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate.

K Honda, C Nakagawa.   

Abstract

The alpha-1 adrenoceptor antagonist effects of the optical isomers of YM-12617 (5-[2-[[2-(o-ethoxyphenoxy)ethyl]amino]propyl]- 2-methoxybenzenesulfonamide HCl), a potent and selective alpha-1 adrenoceptor antagonist, were evaluated in the rabbit lower urinary tract and prostate. R-(-)-YM-12617 (1 X 10(-10) to 3 X 10(-9) M) and S-(+)-YM-12617 (3 X 10(-8) to 3 X 10(-7) M) antagonized phenylephrine-induced contraction in a competitive manner in the urinary bladder base (trigone), proximal urethra and prostate. The mean pA2 value for R-(-)-YM-12617 at the alpha-1 adrenoceptor of trigone, urethra and prostate was 9.91, 9.62 and 9.92, respectively, and that for S-(+)-YM-12617 was 8.09, 7.92 and 7.77, respectively. Therefore, R-(-)-YM-12617 is a 50 to 141 times more potent antagonist than S-(+)-YM-12617 at the alpha-1 adrenoceptor in these tissues. The present results also indicate that the alpha-1 adrenoceptor in the lower urinary tract and prostate can distinguish clearly between the optical isomers of YM-12617. Similar results were obtained in the aorta of rabbits in which a dramatic stereochemical preference of R-(-)-YM-12617 for the alpha-1 adrenoceptor also exists.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877084

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors.

Authors:  A Nishimune; H Yoshiki; J Uwada; A S M Anisuzzaman; H Umada; I Muramatsu
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Tamsulosin: an update of its role in the management of lower urinary tract symptoms.

Authors:  Katherine A Lyseng-Williamson; Blair Jarvis; Antona J Wagstaff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Alpha 1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal alpha 1-adrenoceptor.

Authors:  M C Michel; R Büscher; J Kerker; H Kraneis; W Erdbrügger; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-10       Impact factor: 3.000

Review 4.  Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Authors:  Martin C Michel; Wim Vrydag
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

5.  The stereospecificity of LY253352 for alpha 1-adrenoceptor binding sites in the brain and prostate.

Authors:  H Lepor; M Baumann; E Shapiro
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

6.  Further studies on (+/-)-YM-12617, a potent and selective alpha 1-adrenoceptor antagonist and its individual optical enantiomers.

Authors:  K Honda; C Nakagawa; M Terai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-09       Impact factor: 3.000

Review 7.  Benign prostatic hyperplasia. Current pharmacological treatment.

Authors:  M Jønler; M Riehmann; R C Bruskewitz
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

8.  Electrical and mechanical properties of the capsular smooth muscles of the rabbit prostate in relation to the actions of the alpha 1-adrenoceptor blocker, YM-12617.

Authors:  N Seki; E Nishiye; T Itoh; H Suzuki; H Kuriyama
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

9.  High-affinity specific [3H]tamsulosin binding to alpha 1-adrenoceptors in human prostates with benign prostatic hypertrophy.

Authors:  S Yamada; C Tanaka; T Ohkura; R Mori; R Kimura; O Inagaki; K Honda; K Kawabe
Journal:  Urol Res       Date:  1994
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.